The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

NEW YORK, April 16, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices ...

Vote was 14-0 in favor of new guidelines Previous recommendation was adults 75 years and older and at-risk adults aged 60 to 74 Panel to consider RSV vaccines for adults under 50 in June Panel ...

Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74 Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...

While each vaccine has demonstrated efficacy over at least one RSV season, the duration of protection and optimal revaccination strategy remain unknown. The initial cohort enrolled 24,972 adults ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The experts are due to vote later on Wednesday on whether to recommend a single dose of RSV vaccines to adults aged 50 to 59 years who are at an increased risk of the severe disease. The CDC ...

The 15-member panel voted 14-to-0 to recommend that at-risk adults ages 50 to 59 receive a single dose of RSV vaccine. One of the panel members abstained from voting. The CDC currently recommends ...